Anebulo Pharmaceuticals, Inc.
OTC · CIK 0001815974 · Fiscal year end 0630
Latest reported period: Latest published period
Operating Income
$-4.9M
Net Income
$-4.2M
Eps Basic
-0.1
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-4.9M | - | - |
| Net Income | $-4.2M | - | - |
| Eps Basic | -0.1 | - | - |
| Eps Diluted | -0.1 | - | - |
| Cash And Equivalents | $9.0M | - | - |
| Total Assets | $9.4M | - | - |
| Total Liabilities | $1.5M | - | - |
| Shareholders Equity | $7.9M | - | - |
| Operating Cash Flow | $-2.6M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Anebulo Pharmaceuticals, Inc. | 2026-02-12 | 0001493152-26-006446 |
| 10-Q | Anebulo Pharmaceuticals, Inc. | 2025-11-13 | 0001493152-25-022350 |
| 10-K | Anebulo Pharmaceuticals, Inc. | 2025-09-29 | 0001493152-25-016015 |